PreeclampsiaNCT04794855
Risk Prediction Model of Preeclampsia
An observational study of Preeclampsia and Preeclampsia Severe, run by Peking University Third Hospital at 1 site in China.
Trial summary
Preeclampsia is the main cause of increased maternal and perinatal mortality during pregnancy. Preeclampsia is mainly manifested as hypertension, urine protein, or damage symptoms of other target organs after 20 weeks of pregnancy. Read more about this study
- Who is it for?
- Ages 20 to 50 years, women only
- Conditions the study is for
- Preeclampsia, Preeclampsia Severe
- What is being tested?
- laboratory tests
- How many people
- 2,000 participants
- Where
- 1 siteChina
- Study dates
- 20 Feb 2021to Dec 2024
- How long will I take part?
- 10 Weeks
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- Women only
- No healthy volunteers
- Adult
Study population: 2000 cases anticipated
Who may be able to join
- Pregnant women aged 20-50 years old, primiparas or postparturas,
- and undergoing prenatal examination in Peking University Third Hospital ;
- and deliver live fetuses or stillborn fetuses with normal appearance after 24 weeks.
Who cannot join
- The pregant woman has tumor ,
- or has severe fetal abnormality,
- or terminates the pregnancy before 24 weeks,
- or the fetus dies.
Trial locations and contacts
1 site in 1 country.
China1 site
Peking University Third Hospital
Beijing, Beijing Municipality, 100191
About this study
Official title: Study of the Risk Prediction Model of Preeclampsia
Preeclampsia is the main cause of increased maternal and perinatal mortality during pregnancy. Preeclampsia is mainly manifested as hypertension, urine protein, or damage symptoms of other target organs after 20 weeks of pregnancy. In preeclampsia high-risk group, early intervention and prevention of aspirin treatment can reduce preeclampsia or reduce its complications. Some serological biomarkers, such as placental protein 13 and placental growth factor, are closely related to preeclampsia. The clinical manifestations of preeclampsia are diverse, and the biomarkers distribution of early and late preeclampsia is also different. Multivariate models will be the trend for the prediction of risk of preeclampsia. The deep learning model can train the algorithm layer by layer by unsupervised learning method, and then use the supervised back propagation algorithm for tuning. It has strong capability and flexibility, and has been successfully applied in medical fields, such as the diagnosis of skin cancer.
In this study, maternal clinical data, routine laboratory indicators and biological markers in early pregnancy will be combined, and a deep learning method based on multiple models will be adopted to establish a risk prediction model for early preeclampsia, so as to improve the clinical ability for early diagnosis of preeclampsia. The deep learning method reduces the number of parameters by using spatial relative relation, which can improve the prediction ability of the model. Multi-model method is a less commonly used modeling method, and the models established by this method generally have better stability.
This project combines the above two methods to establish a risk prediction model for preeclampsia, and the research is of great significance.
Read the detailed description
Research objects:
This is a prospective study. About 2000 pregnant women who will take regular prenatal examination in the Department of Obstetrics, Peking University Third Hospital. During 6-8 weeks of gestation, routine laboratory tests, such as liver function, were required before the establishment of obstetric records. The remain serum from routine laboratory tests will be collected and frozen at -80℃ for detection of biological markers after delivery.
Some routine laboratory tests will be carried out with the prenatal examination at 16-18 GWs、26-28 GWs、30-34GWs. The remain serum of the participants will be collected if the routine tests were done.
We will not draw extra blood samples from the participants.
Quality assurance plan:
- Check the patient information and gestational age carefully to obtain the correct cases.
- The samples of hemolysis, lipid turbidity and jaundice should be eliminated to prevent interference with the experimental results.
- The serum was placed in a cryopreservation tube and immediately stored at -70℃.
- Calibration and quality control should be carried out for each batch of testing. Record the results of quality control and start testing after control.
Data dictionary:
(1) General information of the research object: Data on risk factors for preeclampsia were collected at 6-8 weeks of gestation, including age, primipara or pluripara, multiple births, prepregnancy body mass index, preeclampsia history, basal systolic blood pressure, basal diastolic blood pressure, hypertension history, renal history, diabetes history, autoimmune history, etc. The above records will be obtained from the medical records system.
(3) Test results of routine laboratory tests: Laboratory test results, such as total cholesterol, triglycerides, high-density lipoprotein cholesterol, low density lipoprotein cholesterol and lipoprotein a and C reactive protein, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, urea, uric acid, creatinine and cystatine C, D-dimer, neutrophils and lymphocytes ratio, platelet and lymphocyte ratio and so on, the above test results can query from the electronic medical record system.
(4) Biological markers detection: After delivery, the biomarkers will be tested with the 6-8 GWs samples of the 2000 participants, such as the complement factor B, complement factor H, C3, complement C4, matrix metalloproteinases 7, placenta protein 13, soluble vascular endothelial growth factor receptor 1, placental growth factor, fibronectin, etc.
(5) Establishment of database: To input the above original data into the database.
Sample size: About 100 to 160 preeclampsia patients will be collected out of the 2000 participants accoeding to the he incidence of preeclampsia which is 3% to 8%.
The missing data will be reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results according to actual condition.
Statistical analysis plan:
By using univariate logistic regression model, maternal clinical data, routine laboratory tests and biological markers in early pregnancy were divided into two categories: "important indicators" and "general indicators".
The data set was divided into a training set and a test set in a 3:1 ratio for the training and testing of preeclampsia risk prediction model, respectively.
Samples of pregnant women without preeclampsia in the training set were evenly divided into three subsets A, B and C, and the sample set of preeclampsia patients in the training set was called set D.Build A deep learning model with two sets A and D, build A deep learning model with two sets B and D, and build A deep learning model with two sets C and D.These three models are successively referred to as Model 1, Model 2 and Model 3.
Model test method:
Substituting the data of each sample in the test set into the above three deep learning models, the three output values of each sample are obtained, and then the prediction of the type of each sample is obtained based on the average value of the three numbers. Then the prediction results are compared with the sample labels to evaluate the model.
- Conditions
- Preeclampsia, Preeclampsia Severe
- Being tested
- laboratory tests
- Keywords
- Preeclampsia, deep learning, risk factors, risk prediction, biomarkers
- Medical subject headings
- Pre-Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
laboratory testsDiagnostic test
routine laboratory tests and biomarkers tests
| Study group | Role | What they receive |
|---|---|---|
| preganant women | observation from 6-8 weeks. Receives: Diagnostic Test: laboratory tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
preeclampsia
Pre-eclampsia is defined as new hypertension (blood pressure of 140/90 mmHg) with proteinuria (300 mg/24 h) at or after 20 gestational weeks of pregnancy
Measured: pregnancy after 20 getational weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2021
- Study start20 Feb 2021
- Primary completionDec 2022 (estimated)
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PreeclampsiaStudies of the same condition, open and under way.
- More trials run by Peking University Third HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 10 Weeks
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Beijing Forestry university
- Responsible party
- Sponsor
- Investigators
- Keke Jia, master, Study director, study director
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04794855
- Sponsor's protocol ID
- 76439-02
- Status last verified
- Feb 2021
- First submitted
- 9 Mar 2021
- Last updated
- 12 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Risk Prediction Model of Preeclampsia
- ClinicalTrials.gov ID
- NCT04794855
- Acronym / sponsor ID
- 76439-02
- Conditions
- Preeclampsia, Preeclampsia Severe
- Keywords
- Preeclampsia, deep learning, risk factors, risk prediction, biomarkers
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Collaborators
- Beijing Forestry university
- Study start
- 20 Feb 2021 (actual)
- Primary completion
- Dec 2022 (estimated)
- Study completion
- Dec 2024 (estimated)
- First posted
- 12 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Preeclampsia is the main cause of increased maternal and perinatal mortality during pregnancy. Preeclampsia is mainly manifested as hypertension, urine protein, or damage symptoms of other target organs after 20 weeks of pregnancy. In preeclampsia high-risk group, early intervention and prevention of aspirin treatment can reduce preeclampsia or reduce its complications. Some serological biomarkers, such as placental protein 13 and placental growth factor, are closely related to preeclampsia. The clinical manifestations of preeclampsia are diverse, and the biomarkers distribution of early and late preeclampsia is also different. Multivariate models will be the trend for the prediction of risk of preeclampsia. The deep learning model can train the algorithm layer by layer by unsupervised learning method, and then use the supervised back propagation algorithm for tuning. It has strong capability and flexibility, and has been successfully applied in medical fields, such as the diagnosis of skin cancer.
In this study, maternal clinical data, routine laboratory indicators and biological markers in early pregnancy will be combined, and a deep learning method based on multiple models will be adopted to establish a risk prediction model for early preeclampsia, so as to improve the clinical ability for early diagnosis of preeclampsia. The deep learning method reduces the number of parameters by using spatial relative relation, which can improve the prediction ability of the model. Multi-model method is a less commonly used modeling method, and the models established by this method generally have better stability.
This project combines the above two methods to establish a risk prediction model for preeclampsia, and the research is of great significance.
Detailed description
Research objects:
This is a prospective study. About 2000 pregnant women who will take regular prenatal examination in the Department of Obstetrics, Peking University Third Hospital. During 6-8 weeks of gestation, routine laboratory tests, such as liver function, were required before the establishment of obstetric records. The remain serum from routine laboratory tests will be collected and frozen at -80℃ for detection of biological markers after delivery.
Some routine laboratory tests will be carried out with the prenatal examination at 16-18 GWs、26-28 GWs、30-34GWs. The remain serum of the participants will be collected if the routine tests were done.
We will not draw extra blood samples from the participants.
Quality assurance plan:
- Check the patient information and gestational age carefully to obtain the correct cases.
- The samples of hemolysis, lipid turbidity and jaundice should be eliminated to prevent interference with the experimental results.
- The serum was placed in a cryopreservation tube and immediately stored at -70℃.
- Calibration and quality control should be carried out for each batch of testing. Record the results of quality control and start testing after control.
Data dictionary:
(1) General information of the research object: Data on risk factors for preeclampsia were collected at 6-8 weeks of gestation, including age, primipara or pluripara, multiple births, prepregnancy body mass index, preeclampsia history, basal systolic blood pressure, basal diastolic blood pressure, hypertension history, renal history, diabetes history, autoimmune history, etc. The above records will be obtained from the medical records system.
(3) Test results of routine laboratory tests: Laboratory test results, such as total cholesterol, triglycerides, high-density lipoprotein cholesterol, low density lipoprotein cholesterol and lipoprotein a and C reactive protein, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, urea, uric acid, creatinine and cystatine C, D-dimer, neutrophils and lymphocytes ratio, platelet and lymphocyte ratio and so on, the above test results can query from the electronic medical record system.
(4) Biological markers detection: After delivery, the biomarkers will be tested with the 6-8 GWs samples of the 2000 participants, such as the complement factor B, complement factor H, C3, complement C4, matrix metalloproteinases 7, placenta protein 13, soluble vascular endothelial growth factor receptor 1, placental growth factor, fibronectin, etc.
(5) Establishment of database: To input the above original data into the database.
Sample size: About 100 to 160 preeclampsia patients will be collected out of the 2000 participants accoeding to the he incidence of preeclampsia which is 3% to 8%.
The missing data will be reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results according to actual condition.
Statistical analysis plan:
By using univariate logistic regression model, maternal clinical data, routine laboratory tests and biological markers in early pregnancy were divided into two categories: "important indicators" and "general indicators".
The data set was divided into a training set and a test set in a 3:1 ratio for the training and testing of preeclampsia risk prediction model, respectively.
Samples of pregnant women without preeclampsia in the training set were evenly divided into three subsets A, B and C, and the sample set of preeclampsia patients in the training set was called set D.Build A deep learning model with two sets A and D, build A deep learning model with two sets B and D, and build A deep learning model with two sets C and D.These three models are successively referred to as Model 1, Model 2 and Model 3.
Model test method:
Substituting the data of each sample in the test set into the above three deep learning models, the three output values of each sample are obtained, and then the prediction of the type of each sample is obtained based on the average value of the three numbers. Then the prediction results are compared with the sample labels to evaluate the model.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Weeks
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| preganant women | – | Diagnostic Test: laboratory testsobservation from 6-8 weeks. |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- 2000 cases anticipated
Key inclusion criteria (3 listed)
- Pregnant women aged 20-50 years old, primiparas or postparturas,
- and undergoing prenatal examination in Peking University Third Hospital ;
- and deliver live fetuses or stillborn fetuses with normal appearance after 24 weeks.
Key exclusion criteria (4 listed)
- The pregant woman has tumor ,
- or has severe fetal abnormality,
- or terminates the pregnancy before 24 weeks,
- or the fetus dies.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| laboratory testsroutine laboratory tests and biomarkers tests | Diagnostic test | preganant women |
Primary outcome
preeclampsia
Time frame: pregnancy after 20 getational weeks
Pre-eclampsia is defined as new hypertension (blood pressure of 140/90 mmHg) with proteinuria (300 mg/24 h) at or after 20 gestational weeks of pregnancy
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2021.
Related trials for Preeclampsia
Recruiting
Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia
Postpartum Exercise, Cardiometabolic Health
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Severe Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Keke Jia, master study director
study director
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Preeclampsia and Preeclampsia Severe, run by Peking University Third Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
preeclampsia (time frame: pregnancy after 20 getational weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2021.